Your browser doesn't support javascript.
loading
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Fregonese, Federica; Ahuja, Shama D; Akkerman, Onno W; Arakaki-Sanchez, Denise; Ayakaka, Irene; Baghaei, Parvaneh; Bang, Didi; Bastos, Mayara; Benedetti, Andrea; Bonnet, Maryline; Cattamanchi, Adithya; Cegielski, Peter; Chien, Jung-Yien; Cox, Helen; Dedicoat, Martin; Erkens, Connie; Escalante, Patricio; Falzon, Dennis; Garcia-Prats, Anthony J; Gegia, Medea; Gillespie, Stephen H; Glynn, Judith R; Goldberg, Stefan; Griffith, David; Jacobson, Karen R; Johnston, James C; Jones-López, Edward C; Khan, Awal; Koh, Won-Jung; Kritski, Afranio; Lan, Zhi Yi; Lee, Jae Ho; Li, Pei Zhi; Maciel, Ethel L; Galliez, Rafael Mello; Merle, Corinne S C; Munang, Melinda; Narendran, Gopalan; Nguyen, Viet Nhung; Nunn, Andrew; Ohkado, Akihiro; Park, Jong Sun; Phillips, Patrick P J; Ponnuraja, Chinnaiyan; Reves, Randall; Romanowski, Kamila; Seung, Kwonjune; Schaaf, H Simon; Skrahina, Alena; Soolingen, Dick van.
Afiliación
  • Fregonese F; Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada.
  • Ahuja SD; Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, NY, USA.
  • Akkerman OW; University Medical Centre Groningen, Department of Pulmonary Diseases and Tuberculosis, University of Groningen, Groningen, Netherlands.
  • Arakaki-Sanchez D; National Tuberculosis Control Program, Brasilia, Brazil.
  • Ayakaka I; Uganda Tuberculosis Research Consortium, Kampala, Uganda.
  • Baghaei P; Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Bang D; Statens Serum Institut, Copenhagen, Denmark.
  • Bastos M; Epidemiology Department, Social Medicine Institute, University of Rio de Janeiro, Brazil.
  • Benedetti A; Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada.
  • Bonnet M; Institut de Recherche pour le Développement UM233, INSERM U1175, Université de Montpellier, Montpellier, France; Epicentre MSF, Paris, France.
  • Cattamanchi A; Division of Pulmonary and Critical Care Medicine and Curry International Tuberculosis Center, University of California San Francisco, San Francisco, CA, USA.
  • Cegielski P; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Chien JY; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Cox H; Division of Medical Microbiology and Institute of Infectious Diseases and Molecular Medicine University of Cape Town, Cape Town, South Africa.
  • Dedicoat M; Heart of England NHS Foundation Trust, Birmingham, UK.
  • Erkens C; KNCV Tuberculosis Foundation, Team The Netherlands and Elimination, The Hague, Netherlands.
  • Escalante P; Division of Pulmonary and Critical Care Medicine, Department of Medicine, and Mayo Clinic Center for Tuberculosis, Mayo Clinic, Rochester, USA.
  • Falzon D; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Garcia-Prats AJ; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Gegia M; Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Gillespie SH; School of Medicine, University of St Andrews North Haugh, St Andrews, UK.
  • Glynn JR; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
  • Goldberg S; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Griffith D; The University of Texas Health Science Center, Tyler, TX, USA.
  • Jacobson KR; Section of Infectious Diseases, Department of Medicine Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
  • Johnston JC; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Centre for Disease Control, Vancouver, BC, Canada.
  • Jones-López EC; Section of Infectious Diseases, Department of Medicine Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
  • Khan A; Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Koh WJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kritski A; Academic Tuberculosis Program, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Lan ZY; Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Canada.
  • Lee JH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea.
  • Li PZ; Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montreal, Canada.
  • Maciel EL; Laboratory of Epidemiology, Federal University of Espirito Santo, Espírito Santo, Brazil.
  • Galliez RM; State Institute of Infectology São Sebastião, Center for Research and Tuberculosis, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Merle CSC; Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
  • Munang M; Heart of England NHS Foundation Trust, Birmingham, UK.
  • Narendran G; Department of Clinical Research, The National Institute for Research in Tuberculosis, Chennai, India.
  • Nguyen VN; National Lung Hospital, Ba Dinh, Hanoi, Vietnam; Hanoi Medical University, Hanoi, Vietnam.
  • Nunn A; Medical Research Council UK Clinical Trials Unit, University College London, London, UK.
  • Ohkado A; Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • Park JS; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea.
  • Phillips PPJ; Division of Pulmonary & Critical Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Ponnuraja C; The National Institute for Research in Tuberculosis, Chetpet, India.
  • Reves R; Denver Public Health Department, Denver, CO, USA.
  • Romanowski K; British Columbia Centre for Disease Control, Vancouver, BC, Canada.
  • Seung K; Partners in Health, Boston, MA, USA.
  • Schaaf HS; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Skrahina A; Republican Scientific and Practical Centre of Pulmonology and Tuberculosis, Ministry of Health, Minsk, Belarus.
  • Soolingen DV; National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Lancet Respir Med ; 6(4): 265-275, 2018 04.
Article en En | MEDLINE | ID: mdl-29595509
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND / 4_TD Problema de salud: 2_cobertura_universal / 2_enfermedades_transmissibles / 3_neglected_diseases / 3_tuberculosis / 4_tuberculosis Asunto principal: Pirazinamida / Rifampin / Tuberculosis Resistente a Múltiples Medicamentos / Fluoroquinolonas / Etambutol / Antibióticos Antituberculosos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND / 4_TD Problema de salud: 2_cobertura_universal / 2_enfermedades_transmissibles / 3_neglected_diseases / 3_tuberculosis / 4_tuberculosis Asunto principal: Pirazinamida / Rifampin / Tuberculosis Resistente a Múltiples Medicamentos / Fluoroquinolonas / Etambutol / Antibióticos Antituberculosos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article País de afiliación: Canadá